• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Turning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational Updates

    11/9/21 4:01:00 PM ET
    $TPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TPTX alert in real time by email
    • Updated Preliminary Clinical Data Presented for Lead Drug Candidate Repotrectinib and Elzovantinib at the AACR-NCI-EORTC Conference

    • Multiple FDA Interactions Anticipated in Q4 2021 and 1H 2022 for Repotrectinib and Elzovantinib

    • Cash, Cash Equivalents, and Marketable Securities of $1.0 Billion Expected to Fund Current Operations into 2024

    SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported financial results for the third quarter ended September 30, 2021 and provided operational updates.

    "We are encouraged by the progress made across our pipeline, including recent preliminary data presented for repotrectinib and elzovantinib at the AACR-NCI-EORTC meeting," said Athena Countouriotis, M.D., president and CEO. "We look forward to multiple anticipated upcoming FDA interactions including a pre-NDA meeting for repotrectinib in ROS1-positive non-small cell lung cancer."

    Third quarter and recent highlights include:

    REPOTRECTINIB, ROS1/TRK INHIBITOR

    • Second Breakthrough Therapy Designation (BTD) granted by the U.S. Food and Drug Administration (FDA) for repotrectinib for the treatment of patients with advanced solid tumors that have an NTRK gene fusion who have progressed following treatment with one or two prior TRK tyrosine kinase inhibitors, with or without prior chemotherapy, and have no satisfactory alternative treatments. BTD is granted by the FDA to expedite the development and regulatory review of an investigational medicine that is intended to treat a serious or life-threatening condition.



      The company anticipates discussing next steps towards registration of repotrectinib in patients with NTRK-positive TKI-pretreated advanced solid tumors at a Type B meeting with the FDA in the fourth quarter of 2021.



    • Progress in the Phase 2 TRIDENT-1 registrational study of repotrectinib, where the company reported early interim data at the AACR-NCI-EORTC conference. Utilizing an August 26, 2021 data cutoff for the updated Phase 2 dataset and a July 22, 2019 data cutoff for Phase 1, the preliminary efficacy analysis across multiple cohorts pooled from the Phase 1 and Phase 2 portions of the study demonstrated confirmed objective response rates (cORRs) of 39% in ROS1-positive NSCLC patients pretreated with one prior TKI and prior platinum-based chemotherapy (EXP2: n=23); 30% in ROS1-positive NSCLC patients pretreated with two prior TKIs without prior chemotherapy (EXP-3: n=10); 38% in ROS1-positive NSCLC patients pretreated with one prior TKI without prior chemotherapy (EXP-4: n=39); 41% in NTRK-positive TKI-naïve solid tumor patients (EXP-5: n=17); and 48% in NTRK-positive TKI-pretreated solid tumor patients (EXP-6: n=23). The cORRs in patients with solvent front mutations (SFMs) were 53% in ROS1-positive TKI-pretreated NSCLC patients with a G2032R SFM (n=15), and 62% in NTRK-positive TKI-pretreated solid tumor patients with NTRK SFMs (n=13).   Phase 2 responses were determined by physician assessment, and Phase 1 responses were determined by blinded independent central review (BICR).



      The safety analysis from 301 treated patients from the pooled Phase 1 and Phase 2 portions of TRIDENT-1 across all cohorts demonstrated that repotrectinib was generally well tolerated, with the majority of treatment related adverse events reported as grade 1 or 2.
    • The company anticipates reporting topline BICR data from all of the ROS1-positive NSCLC cohorts from TRIDENT-1 and discussing the BICR data with the FDA at a pre-NDA meeting, in the second quarter of 2022. The company plans to discuss available BICR data in at least 50 TKI-naïve and 50 TKI-pretreated patients with at least six months of follow-up for the majority of responders.



    • Progress in the Phase 1/2 CARE study of repotrectinib in pediatric and young adult patients, where the company reported early data at the SIOP Congress. Utilizing an August 2, 2021 data cutoff, the company highlighted preliminary responses by physician assessment and a generally tolerable safety profile. Eight patients were evaluable for efficacy, including four TKI-naïve and four TKI-pretreated patients. Three TKI-naïve patients (two with NTRK fusion solid tumors and one with ROS1 fusion IMT) achieved confirmed responses, including 1 complete response.



    ELZOVANTINIB (TPX-0022), MET/SRC/CSF1R INHIBITOR

    • Progress in the Phase 1 SHIELD-1 study of elzovantinib, Turning Point's MET, SRC and CSF1R inhibitor, where updated preliminary data from the dose finding portion of the study reported at the AACR-NCI-EORTC conference highlighted clinical activity, including objective responses across multiple tumor types and a generally tolerable safety profile utilizing an August 23, 2021 data cutoff. Among 11 MET TKI-naïve NSCLC patients, four achieved confirmed responses for a cORR of 36% across all dose levels. Among nine MET TKI-naïve gastric/gastroesophageal junction (GC/GEJ) patients, three achieved confirmed responses for a cORR of 33% across all dose levels. Elzovantinib was generally well tolerated, with the most frequently reported TEAE being dizziness (65%) of which 94% of reported cases were grade 1 or grade 2. Responses were determined by physician assessment.



    • Completion of an End of Phase 1 Meeting with the FDA focused on next steps in NSCLC, where the design of the planned Phase 2 portion of the SHIELD-1 study and the recommended Phase 2 dose (RP2D) were discussed. The company proposed a RP2D of 40 mg QD to 40 mg BID at the meeting based on available data. The FDA recommended that the company explore an additional intermediate dose level using the QD titration to BID dosing strategy in at least six to 10 patients prior to starting the Phase 2 portion of the study.



      Patient screening at the intermediate dose level (60 mg QD to 60 mg BID) is ongoing and the company plans to enroll at least six to 10 patients at this dose level and provide data from this dose level to the FDA, with the intention of revising the SHIELD-1 study into a potentially registrational Phase 1/2 study and initiating the Phase 2 portion in 2022. The company also continues to enroll patients in the Phase 1 dose expansion portion of the study at 40 mg QD to 40 mg BID.



    • FDA feedback on the development path for elzovantinib in gastric/gastroesophageal junction (GEJ) cancer is anticipated in the fourth quarter of 2021.



    • The company announced a clinical collaboration with EQRx to evaluate elzovantinib in combination with aumolertinib, EQRx's drug candidate targeting EGFR, in patients with EGFR mutant MET-amplified advanced NSCLC. The company anticipates initiating the SHIELD-2 combination study of elzovantinib and aumolertinib in mid-2022, pending filing of an investigational new drug (IND) application by the FDA.

    TPX-0046, RET INHIBITOR

    • Progress in the ongoing dose-finding portion of the Phase 1/2 SWORD-1 study, where the company continues to evaluate multiple doses and schedules to further characterize the pharmacokinetics, safety, and efficacy profile before determining the RP2D.



    TPX-0131, ALK INHIBITOR

    • Ongoing patient dosing in the Phase 1/2 FORGE-1 study of TPX-0131 in locally advanced or metastatic TKI-pretreated ALK-positive NSCLC. The study endpoints include safety and tolerability, determination of the recommended Phase 2 dose, pharmacokinetics, and any early signals of efficacy.

    DISCOVERY

    • Continued advancement of four internal discovery programs targeting aberrant GTPase signaling known to drive genomically defined cancers with significant unmet medical need. The most advanced programs target KRAS G12D and the p21 activated kinase, or "PAK" family. Turning Point is targeting 2 development candidates in the second half of 2022 with a goal to achieve at least one new IND per year beginning in 2023.



    Third Quarter Financial Results

    • R&D Expenses: Research and development expenses were $48.9 million in the quarter, compared to $32.2 million in the third quarter of 2020. The $16.7 million increase was primarily driven by the year-over-year increase in investments to develop repotrectinib, elzovantinib, TPX-0046 and TPX-0131, discovery efforts and personnel expenses.



    • G&A Expenses: General and administrative expenses were $18.2 million compared to $11.3 million in the third quarter of 2020. This increase was primarily due to higher personnel expenses from an increase in head count and professional fees, including those associated with launch readiness.



    • Net Income/Loss: Net loss was $66.3 million compared to a net loss of $17.7 million for the third quarter of 2020. The net loss in the third quarter of 2020 was partially offset by the $25 million recorded as a result of the upfront payment from Zai Lab under the company's license agreement for repotrectinib in Greater China.



    • Cash Position: Cash, cash equivalents and marketable securities at September 30, 2021 totaled approximately $1.0 billion, reflecting a net decrease of $86.5 million in the first three quarters of 2021. Turning Point projects its cash position funds current operations into 2024.

    Webcast and Conference Call

    Turning Point will webcast its Quarterly Update Conference Call today, November 9 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Countouriotis will host the call, which will be accessible through the "Investors" section of tptherapeutics.com or by dialing (877) 388-2118 (in the United States) or (470) 495-9489 (outside the U.S.) using conference ID 3118428. A replay will be available through the "Investors" section of www.tptherapeutics.com.

    About Turning Point Therapeutics Inc.

    Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company's pipeline of drug candidates also includes elzovantinib, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor, which is being studied in a Phase 1/2 trial of previously treated patients with ALK-positive advanced or metastatic non-small cell lung cancer. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.

    Forward Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "plans", "will", "believes," "anticipates," "expects," "intends," "goal," "potential" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of Turning Point Therapeutics' drug candidates, repotrectinib, elzovantinib, TPX-0046 and TPX-0131, the results, conduct, progress and timing of Turning Point Therapeutics' research and development programs and clinical trials, plans regarding future data presentations, clinical trials, regulatory meetings and regulatory submissions, the regulatory approval path for repotrectinib, and the strength of Turning Point Therapeutics' balance sheet and the adequacy of cash on hand. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Turning Point Therapeutics' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Turning Point Therapeutics' business in general, risks and uncertainties related to the impact of the COVID-19 pandemic to Turning Point Therapeutics' business and the other risks described in Turning Point Therapeutics' filings with the Securities and Exchange Commission (SEC), including its quarterly report on Form 10-Q filed with the SEC on November 9, 2021. All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    TURNING POINT THERAPEUTICS, INC.

    Balance Sheet Data

    (In thousands)

    (unaudited)

     September 30,  December 31, 
     2021  2020 
    Balance Sheet Data:       
    Cash, cash equivalents, and marketable securities$1,036,014  $1,122,508 
    Working capital 1,008,388   1,106,287 
    Total assets 1,058,985   1,136,713 
    Accumulated deficit (438,278)  (280,176)
    Total stockholders' equity$1,017,337  $1,109,898 
            

    TURNING POINT THERAPEUTICS, INC.

    STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (In thousands, except share and per share amounts)

    (unaudited)

     Three Months Ended

    September 30,
      Nine Months Ended

    September 30,
     2021  2020  2021  2020 
    Revenue$460  $25,000  $30,829  $25,000 
    Operating expenses:               
    Research and development 48,889   32,213   134,802   79,136 
    General and administrative 18,224   11,326   55,386   59,761 
    Total operating expenses 67,113   43,539   190,188   138,897 
    Loss from operations (66,653)  (18,539)  (159,359)  (113,897)
    Other income, net 328   834   1,257   3,981 
    Net loss (66,325)  (17,705)  (158,102)  (109,916)
    Unrealized (loss) / gain on marketable securities, net of tax (18)  (606)  (225)  141 
    Comprehensive loss$(66,343) $(18,311) $(158,327) $(109,775)
    Net loss per share, basic and diluted$(1.34) $(0.42) $(3.21) $(2.82)
    Weighted-average common shares outstanding, basic and diluted 49,426,496   42,185,824   49,185,693   38,914,789 

    Contact:

    Adam Levy

    [email protected] 

    858-867-6366



    Primary Logo

    Get the next $TPTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TPTX

    DatePrice TargetRatingAnalyst
    5/20/2022$58.00Buy
    BofA Securities
    3/1/2022$50.00 → $45.00Hold
    Stifel
    2/10/2022$120.00 → $85.00Overweight
    Wells Fargo
    1/21/2022$115.00 → $105.00Outperform
    Oppenheimer
    12/7/2021Outperform
    Cowen & Co.
    11/10/2021$150.00 → $115.00Outperform
    Oppenheimer
    10/12/2021$178.00 → $162.00Buy
    HC Wainwright & Co.
    10/11/2021Market Outperform → Market Perform
    JMP Securities
    More analyst ratings

    $TPTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Nicholson Garry A (tax withholding)

      4 - Turning Point Therapeutics, Inc. (0001595893) (Issuer)

      8/17/22 4:43:52 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Machado Patrick (withholding obligation)

      4 - Turning Point Therapeutics, Inc. (0001595893) (Issuer)

      8/17/22 4:41:51 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: George Simeon returned $171,278,160 worth of shares to the company (2,253,660 units at $76.00) to cover taxes

      4 - Turning Point Therapeutics, Inc. (0001595893) (Issuer)

      8/17/22 4:40:00 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TPTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Axonis Therapeutics Announces $115 Million Series A Financing

      -- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent

      10/30/24 6:00:00 AM ET
      $AKRO
      $APLS
      $AUPH
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Chemicals
      Consumer Durables
    • venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies

      - venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo

      8/1/24 8:00:00 AM ET
      $AKRO
      $APLS
      $AUPH
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Chemicals
      Consumer Durables
    • NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and

      2/27/24 9:00:00 AM ET
      $BMRN
      $ENOV
      $OPCH
      $SYNH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services

    $TPTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Turning Point Therapeutics Inc.

      SC 13G - Turning Point Therapeutics, Inc. (0001595893) (Subject)

      2/14/22 3:02:35 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Turning Point Therapeutics Inc. (Amendment)

      SC 13G/A - Turning Point Therapeutics, Inc. (0001595893) (Subject)

      2/14/22 2:35:02 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Turning Point Therapeutics Inc. (Amendment)

      SC 13G/A - Turning Point Therapeutics, Inc. (0001595893) (Subject)

      2/9/22 10:01:27 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TPTX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Turning Point Therapeutics Inc.

      15-12G - Turning Point Therapeutics, Inc. (0001595893) (Filer)

      8/29/22 4:30:18 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Turning Point Therapeutics Inc.

      EFFECT - Turning Point Therapeutics, Inc. (0001595893) (Filer)

      8/23/22 12:15:10 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Turning Point Therapeutics Inc.

      S-8 POS - Turning Point Therapeutics, Inc. (0001595893) (Filer)

      8/17/22 9:02:25 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TPTX
    Financials

    Live finance-specific insights

    See more

    $TPTX
    Leadership Updates

    Live Leadership Updates

    See more

    $TPTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bristol Myers Squibb Reports Second Quarter Financial Results for 2022

      Reports Second Quarter Revenues of $11.9 Billion, an Increase of 2% YoY; or 5% When Adjusted for Foreign Exchange Posts Second Quarter Earnings Per Share of $0.66 and Non-GAAP EPS of $1.93; Includes Net Impact of ($0.14) per share for GAAP and Non-GAAP EPS Due to Acquired IPRD1 Charges and Licensing Income Delivers Robust Revenue Growth of 11% from In-Line Products and New Product Portfolio; or 16% When Adjusted for Foreign Exchange Expands Oncology Franchise with New Indications for Opdivo and Planned Acquisition of Precision Oncology Company, Turning Point Therapeutics Strengthens Cell Therapy Franchise with Broadest Label for Breyanzi in Relapsed or Refractory Large B-cell Lymph

      7/27/22 6:59:00 AM ET
      $BMY
      $IMTX
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines

      Strategic Expansion of Turning Point Precision Oncology Portfolio TPX-4589 (LM-302) Currently in Two Ongoing Phase 1 Studies Agreement Includes Potential Broader Scope to Collaborate on up to Three Additional ADC Programs SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, announced today that it has entered into an exclusive license agreement with LaNova Medicines Limited (LaNova) to develop and commercialize LM-302, a novel antibody drug conjugate (ADC) targeting Claudin18.2, in the U.S. and rest of the world, excluding Greater Chi

      5/5/22 9:00:00 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study

      In a total of 71 TKI-naïve patients, confirmed objective response rate (cORR) of 79% (95% CI: 68, 88)In the TKI-naïve population with approximately 10 months of follow-up, initial estimated durability of response and progression free survival of 85% and 82% at 12-month landmarks, respectivelyIn TKI-pretreated patients, cORR of 42% in those treated with 1 TKI and platinum-based chemotherapy (EXP-2), cORR of 28% in those treated with two TKIs (EXP-3), and cORR of 36% in those treated with 1 TKI (EXP-4) In TKI-pretreated patients with an identified ROS1 G2032R solvent front mutation, cORR of 59%Pre-NDA meeting anticipated this quarter to discuss potential NDA in ROS1-positive NSCLC Conference C

      4/12/22 4:46:10 PM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and

      2/27/24 9:00:00 AM ET
      $BMRN
      $ENOV
      $OPCH
      $SYNH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services
    • Turning Point Therapeutics Announces Appointment of Steve Sabus as Chief Commercial Officer

      SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the appointment of Steve Sabus as Chief Commercial Officer, effective as of May 31, 2022. Prior to Turning Point, Mr. Sabus spent 15 years in roles with increasing levels of sales responsibility at Astellas Pharma, most recently serving as the Head of Oncology leading a group of over 300 team members. In this role he provided executive leadership to scale the company's $3 billion U.S. oncology franchise by launching and growing new products. His achievements include su

      5/16/22 8:30:00 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Turning Point Therapeutics Announces Appointment of Brian Sun, M.S., J.D., as Incoming General Counsel

      SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Brian Sun, M.S., J.D. as its incoming Senior Vice President and General Counsel, effective as of April 11, 2022. Mr. Sun currently serves as Senior Vice President and General Counsel at Sorrento Therapeutics, Inc, a Nasdaq-listed company, where he leads the legal function and team. Previously, he worked at Prometheus Laboratories and Hologic and served as outside general counsel to early-stage biotechnology companies. Earlier in his career, Mr

      3/29/22 9:00:00 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on Turning Point Therapeutics with a new price target

      BofA Securities initiated coverage of Turning Point Therapeutics with a rating of Buy and set a new price target of $58.00

      5/20/22 7:27:32 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel reiterated coverage on Turning Point with a new price target

      Stifel reiterated coverage of Turning Point with a rating of Hold and set a new price target of $45.00 from $50.00 previously

      3/1/22 11:13:37 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo reiterated coverage on Turning Point with a new price target

      Wells Fargo reiterated coverage of Turning Point with a rating of Overweight and set a new price target of $85.00 from $120.00 previously

      2/10/22 7:06:48 AM ET
      $TPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care